

WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in Inflammatory Bowel Disease and sporadic colorectal cancer. Serafino *et al.*

SUPPLEMENTARY Table S1

Supplementary Table S1. List of antibodies used for immunohistochemical analysis

Antigen	Host	Cat. #	Working dilution	Supplier
β -catenin	Mouse (monoclonal)	610154 (Clone 14)	1:150	BD Transduction Labs (Palo Alto, CA, USA)
E-cadherin	Mouse (monoclonal)	610182 (Clone 36)	1:200	BD Transduction Labs (Palo Alto, CA, USA)
APC	Rabbit (monoclonal)	ab40778	1:100	Abcam (Cambridge, MA, USA)
c-Myc	Mouse (monoclonal)	sc-40	1:50	Santa Cruz Biotechnology (Dallas, TX, USA)
Cyclin-D1	Mouse (monoclonal)	sc-8396	1:50	Santa Cruz Biotechnology (Dallas, TX, USA)

Supplementary Table S2. Mean score values and significance (Student's *t* Test) of the quantitative analysis reported in Supplementary Figure S1. *P* value threshold: *P* < 0.05. Significant values are highlighted in red

HUMAN	Mean score	±S.D.	<i>P</i> vs NM	<i>P</i> vs previous Stage	RAT	Mean score	±S.D.	<i>P</i> vs NM	<i>P</i> vs previous Stage
Nuclear β-catenin									
NM	5	0.00			NM	5	0.00		
IBD	7	2.74	0.177807808		IBD	8	2.74	0.070483997	
LD	10	6.12	0.141927448	0.20800000 vs IBD	LD	16	5.48	0.010899699	0.002837846 vs IBD
HD	20	0.00	1.18835x10⁻¹²	0.022048174 vs LD	HD	20	0.00	1.18835x10⁻¹²	0.179236763 vs LD
IS	15	5.48	0.010899699	0.179236763 vs HD	IS	16	5.48	0.010899699	0.179236763 vs HD
K	6	2.24	0.373900966	0.011056493 vs IS	K	14	5.48	0.021311641	0.373900966 vs IS
Membranous β-catenin									
NM	20	0.00			NM	14	5.48		
IBD	20	0.00	0.373900966		IBD	18	4.47	0.177807808	
LD	16	5.48	0.177807808	0.179236763 vs IBD	LD	11	5.48	0.208000000	0.024896163 vs IBD
HD	5	0.02	1.18203x10⁻¹²	0.010928395 vs LD	HD	5	0.00	0.021311641	0.070483997 vs LD
IS	6	2.24	0.000151011	0.373900966 vs HD	IS	6	2.24	0.01613009	0.373900966 vs HD
K	17	6.71	0.373900966	0.051374431 vs IS	K	14	5.34	0.373900966	0.01619462 vs IS
Total E-cadherin									
NM	16	5.48			NM	16	5.48		
IBD	18	4.47	0.373900966		IBD	18	4.47	0.373900966	
LD	14	5.48	0.373900966	0.177807808 vs IBD	LD	12	4.47	0.177807808	0.070483997 vs IBD
HD	18	4.47	0.373900966	0.177807808 vs LD	HD	6,4	4.93	2.53213x10⁻⁶	0.071076798 vs LD
IS	4,6	4.93	0.003981595	0.004278734 vs HD	IS	1	0.00	0.003602233	0.070483997 vs HD
K	10	0.00	0.070483997	0.070483997 vs IS	K	10	0.00	0.070489127	1.4762x10⁻¹⁰ vs IS
Membranous E-cadherin									
NM	20	0.00			NM	20	0.00		
IBD	20	0.00	0.373900966		IBD	10	0.00	9.5233x10⁻¹¹	
LD	14	5.48	0.070483997	0.071262472 vs IBD	LD	8	2.74	0.000608185	0.183594823 vs IBD
HD	7	2.74	0.000445954	0.004635839 vs LD	HD	6	2.24	0.000151011	0.177807808 vs LD
IS	5	0.00	1.88619x10⁻¹¹	0.177835707 vs HD	IS	5	0.00	1.8862x10⁻¹¹	0.373900966 vs HD
K	14	5.48	0.070483997	0.021504336 vs IS	K	20	0.00	0.373900966	1.2382x10⁻¹¹ vs IS

HUMAN	Mean score	±S.D.	P vs NM	P vs previous Stage	RAT	Mean score	±S.D.	P vs NM	P vs previous Stage
Total APC									
NM	10	0.00			NM	10	0.00		
IBD	20	0.00	4.32343x10⁻⁹		IBD	18	4.47	0.01613009	
LD	20	0.00	2.76078x10⁻¹⁰	0.649988954 vs IBD	LD	18	4.47	0.01613009	0.01613009 vs IBD
HD	16	5.48	0.057668886	0.178381187 vs LD	HD	16	4.47	0.373900966	0.070483997 vs LD
IS	12,5	5.00	0.391002219	0.181690114 vs HD	IS	1	0.00	1.4645x10⁻¹⁴	0.005336446 vs HD
K	4	4.93	0.057668886	4.34235x10⁻⁵ vs IS	K	4,6	4.93	0.070483997	0.178124329 vs IS
Nuclear APC									
NM	10	0.00			NM	10	0.00		
IBD	10	0.00	0.422649731		IBD	10	0.00	0.422649731	
LD	10	0.00	0.422649731	0.547089186 vs IBD	LD	10	0.00	0.422649731	1 vs IBD
HD	4,6	2.74	0.422649731	0.072048725 vs LD	HD	7	2.74	0.422649731	0.070484204 vs LD
IS	1	0.00	4.38548x10⁻⁵	0.177835707 vs HD	IS	5	0.00	4.43852x10⁻⁷	0.177808092 vs HD
K	1	0.00	4.43852x10⁻⁷	0.43137677 vs IS	K	5	0.00	4.43852x10⁻⁷	1 vs IS
Total c-Myc									
NM	1	0.00			NM	2,8	4.02		
IBD	14	5.48	0.006057526		IBD	10	0.00	0.01613009	
LD	20	0.00	4.61371x10⁻¹³	0.071262472 vs IBD	LD	16	5.48	0.005129326	0.070483997 vs IBD
HD	12,5	5.00	0.019312445	0.057668886 vs LD	HD	12	4.47	1.33584x10⁻⁶	0.177807808 vs LD
IS	10	0.00	1.37276x10⁻⁷	0.422649731 vs HD	IS	10	0.00	0.01613009	0.373900966 vs HD
K	3,25	4.50	0.391002219	1.37276E-07 vs IS	K	6,4	4.93	0.177807808	0.177807808 vs IS
Nuclear c-Myc									
NM	5	0.00			NM	6	2.24		
IBD	13	6.71	0.056		IBD	14	5.48	0.01613009	
LD	18	4.47	0.002888981	0.088987311 vs IBD	LD	20	0.00	0.000151011	0.070483997 vs IBD
HD	16,67	5.77	0.07282735	0.422649731 vs LD	HD	17,5	5.00	0.015392438	0.391002219 vs LD
IS	20	0.00	4.94047x10⁻⁸	0.423227369 vs HD	IS	18	4.47	0.01613009	0.391002219 vs HD
K	5	0.00	0.373900966	4.94047E-08 vs IS	K	8	2.74	0.177807808	0.021742978 vs IS
Total Cyclin-D1									
NM	1	0.00			NM	1	0.00		
IBD	6,4	4.93	0.070483997		IBD	10	0.00	1.37276x10⁻⁷	
LD	1	0.00	0.373900966	0.070484061 vs IBD	LD	2	4.02	0.373900966	1.37276x10⁻⁷ vs IBD

HD	1	0.00	0.373900966	0.43137677	vs LD	HD	2	4.02	0.373900966	0.373900966	vs LD
IS	8,2	4.02	0.01613009	0.01613009	vs HD	IS	8,4	7.89	0.104076293	0.071088282	vs HD
K	18	4.47	0.001050578	1.03792x10⁻⁶	vs IS	K	16	5.48	0.003602233	0.248146391	vs IS
Nuclear Cyclin-D1											
NM	5	0.00				NM	5	0.00			
IBD	5	0.00	0.373900966			IBD	12	4.47	0.024896163		
LD	5	0.00	0.373900966	0.814902011	vs IBD	LD	5	0.00	0.373900966	0.0249018	vs IBD
HD	5	0.00	0.373900966	0.411406737	vs LD	HD	8	2.74	0.070483997	0.070483999	vs LD
IS	7	2.74	0.177807808	0.177750897	vs HD	IS	13	6.71	0.056000000	0.089009343	vs HD
K	17	6.71	0.01613009	0.021742978	vs IS	K	20	0.00	1.89731x10⁻¹⁵	0.080097572	vs IS

Supplementary Table S3. Wnt pathway targeting compounds in clinical trials

Compound	Target	Modality	Tumor Type	Clinical Trials Identifier	Phase	Sponsor
LGK974	Porcupine (essential for Wnt protein secretion and function)	Small molecule	Melanoma; Breast Neoplasms; Lobular Carcinoma; Triple-negative Breast Cancer; Pancreatic Adenocarcinoma	NCT01351103	Phase 1	Novartis Pharmaceuticals
BHQ880	DKK-1	Antibody	Multiple Myeloma	NCT00741377 NCT01337752 NCT01302886	Phase 1 Phase 2 Phase 2	Novartis Pharmaceuticals
DKN-01	DKK-1	Antibody	Multiple Myeloma; Solid Tumors; Non-Small Cell Lung Cancer	NCT01457417 NCT01711671	Phase 1 Phases 1/2	Dekkun Corporation
OMP-18R5	Fzd receptors	Antibody	Solid Tumors	NCT01345201 NCT01957007	Phase 1 Phase 1	OncoMed Pharmaceuticals, Inc
OMP-54F28	Wnt ligands	Antibody	Solid Tumors	NCT01608867	Phase 1	OncoMed Pharmaceuticals, Inc Collaborator: Bayer
PRI-724	β -catenin/CBP antagonist	Small molecule	Myeloid Leukemia; Pancreatic Adenocarcinoma; Solid tumor	NCT01606579 NCT01764477 NCT01302405	Phases 1/2 Phase 1 Phase 1	Prism Pharma Co., Ltd Collaborator: inVentiv Health Clinical

Detailed information available on <http://clinicaltrials.gov>